Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (October 2020)
21 slides from Immutep's shareholder meeting presentation, Oct 27, 2020
Slide 1: 2020 AGM Presentation
2020 AGM Presentation Marc Voigt, CEO The global leader in developing LAG-3 therapeutics
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cla
Slide 3: General Overview
General Overview Corporate Snapshot Continued global Compelling clinical Strengthened IMM (ASX) leadership in LAG- data reported partnerships & Ticker symbols IMMP (NASDAQ) 3 therapeutics from multiple collaborations with four product clinical trials with pharma Securities on candidates in supportin
Slide 4: Encouraging efficacy results for efti throughout FY20
Encouraging efficacy results for efti throughout FY20 Building • 6-month landmark showed improvement compared to placebo group AIPAC Breast • 48.3% Overall Response Rate compared to 38.4% in placebo group efti’s Cancer • Favourable results in different predefined patient subgroups intrinsic value •
Slide 5: Other Highlights
Other Highlights Post FY20 • Limited impacts to trial recruitment from COVID-19: • AIPAC and INSIGHT-004 enrolment complete • TACTI-002 >80% enrolment complete Encouraging TACTI-002 data presented at ESMO • IMP761 stable CHO cell line developed with sufficient yields and the manufacturing steps adva
Slide 6: Partner & Collaboration Highlights
Partner & Collaboration Highlights Novartis CYTLIMIC IMP701 (LAG525) - Phase II Phase I studies of peptide vaccine, CYT001 in advanced • 5 clinical trials advancing in multiple cancer indications or metastatic solid cancer - more than 1,000 patients • Positive results from YNP01 trial - 70% of patie
Slide 7: Key Financials
Key Financials • Licensing revenue increased significantly mainly due to a FY20 FY19 GSK milestone payment of £4M (A$7.49M) Revenue and other income • Research material sales decreased due to a single bigger A$16.5M $7.5M purchase by a customer in FY19 G&A Expenses A$6.3M $6.4M • A$1.44M cash rebate
Slide 8: Immutep Pipeline Update
Immutep Pipeline Update
Slide 9: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview Company Program Preclinical Phase I Phase II Phase III Total Trials Patients Agonist Eftilagimod Alpha Eftilagimod Alpha 4 3 22 4246 455 BMS Relatlimab 8 25 2 35 9,982 Novartis LAG525 (IMP701) 1 4 1,122 LAG525 (leramilimab) 1 4 5 1,069 B.I. B.I. BI754111 BI754111
Slide 10: Immutep's Market Opportunity
Immutep’s Market Opportunity Estimated Market Opportunity by 2025 250 200 Exposure to Oncology1 $176.50 billion Market Value US$ billion three very large Autoimmune2 150 and growing $149.40 billion pharmaceutical markets 100 Infectious Disease3 $86.20 billion 50 0 0 2 4 6 8 10 CAGR % 1) https://www.
Slide 11: Immutep Controlled Immunotherapy Pipeline
Immutep Controlled Immunotherapy Pipeline* Commercial Market Size(6) Program Preclinical Phase I Phase II Late Stage(5) Rights (by) Metastatic Breast Cancer (Chemo – IO) US$12.7 billion AIPAC (2024) Non-Small-Cell Lung Carcinoma (IO – IO) (1) US$33.9 billion TACTI-002 (2026) Head and Neck Squamous C
Slide 12: Efti: Potential Pipeline in a Product
Efti: Potential Pipeline in a Product Potential for use in various Efti is the ideal candidate to combine combination settings with available cancer treatments First-in-Class MHCII agonist Good safety profile Encouraging efficacy data Low cost of goods
Slide 13: Other Eftilagimod Alpha Partnerships
Other Eftilagimod Alpha Partnerships • EOC, an Eddingpharm spin-off holding the Chinese rights for efti, Phase I study in MBC ongoing • Milestone and royalty bearing partnership • Spin off from NEC, Japan: aims to develop cancer drugs discovered by artificial intelligence → mainly cancer vaccines •
Slide 14: Broad potential in targeting auto-reactive memory T cells with IMP761
Broad potential in targeting auto-reactive memory T cells with IMP761 THE PRESENT: FIGHTING THE SYMPTOMS Treating general inflammation: corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs THE FUTURE: FIGHTING THE CAUSE Treating the disease process: silencing the few autoimmune memory T
Slide 15: Immutep Out-Licensed Immunotherapy Pipeline
Immutep Out-Licensed Immunotherapy Pipeline* Commercial Program Preclinical Phase I Phase II Late Stage(1) Updates Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Novartis currently has five clinical trials ongoing for Oncology Global Rights L
Slide 16: EAT COVID trial
EAT COVID trial • Window of opportunity to boost the immune response prior to deterioration requiring intensive care unit (ICU) admission and mechanical ventilation • Goal is to: • prevent T cell exhaustion and profound lymphopenia • eradicate the COVID-19 virus • avoid any extensive organ tissue da
Slide 17: EAT COVID trial
EAT COVID trial EAT COVID is an investigator-initiated trial evaluating efti in hospitalised COVID-19 patients Aims to “push the gas” on a patient’s immune response to prevent Phase II severe COVID-19 symptoms requiring intensive care and leading to Placebo controlled, double blinded and 1:1 randomi
Slide 18: Outlook
Outlook
Slide 19: 2020 & 2021 News Flow
2020 & 2021 News Flow* 2020 2021 • AIPAC - interim Overall Survival data to be • Final data from TACTI-002 Parts A and C presented at San Antonio Breast Cancer • Final data from INSIGHT-004 Symposium 2020: Dec 2020 • Ongoing regulatory engagement • TACTI-002 - more data from NSCLC 1st line: througho
Slide 20: Summary
Summary Global leadership position 10 active clinical trials in LAG-3 with four related (including partnered product candidates in products) with further immuno-oncology and significant data read-outs autoimmune diseases throughout 2020 and 2021 Compelling clinical data Established commercial from e
Slide 21: Thank you
@ Immutep LAG-3 IMMUNOTHERAPY Thank you